Maria Beumont

4.9k total citations
55 papers, 1.8k citations indexed

About

Maria Beumont is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Maria Beumont has authored 55 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hepatology, 35 papers in Epidemiology and 24 papers in Infectious Diseases. Recurrent topics in Maria Beumont's work include Hepatitis C virus research (43 papers), HIV/AIDS drug development and treatment (22 papers) and Liver Disease Diagnosis and Treatment (17 papers). Maria Beumont is often cited by papers focused on Hepatitis C virus research (43 papers), HIV/AIDS drug development and treatment (22 papers) and Liver Disease Diagnosis and Treatment (17 papers). Maria Beumont collaborates with scholars based in United States, Belgium and France. Maria Beumont's co-authors include Gastón Picchio, Roger J. Pomerantz, Geethanjali Dornadula, Kelly Henning, Hui Zhang, Sandra De Meyer, F. Lunel, Bruno Halioua, Rolf van Heeswijk and Stefan Zeuzem and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Maria Beumont

53 papers receiving 1.7k citations

Peers

Maria Beumont

EPIDE

HEPAT

VIROL

RHEUM

Shahin Gharakhanian France

Ignacio de los Santos Spain

Gabriella Verucchi Italy

Jean‐Jacques Lefrère France

G Scullard United Kingdom

Anders Sönnerborg Sweden

Mark Danta Australia

Juergen Rockstroh Germany

Javier García‐Samaniego Spain

David Rey France

Shahin Gharakhanian France

Maria Beumont

1.0k ×0.9

EPIDE

1.0k ×0.9

HEPAT

697 ×0.9

401 ×1.5

VIROL

121 ×1.0

RHEUM

Citations per year, relative to Maria Beumont Maria Beumont (= 1×) peers Shahin Gharakhanian

Countries citing papers authored by Maria Beumont

Since Specialization

Citations

This map shows the geographic impact of Maria Beumont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Beumont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Beumont more than expected).

Fields of papers citing papers by Maria Beumont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Beumont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Beumont. The network helps show where Maria Beumont may publish in the future.

Co-authorship network of co-authors of Maria Beumont

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Beumont. A scholar is included among the top collaborators of Maria Beumont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Beumont. Maria Beumont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agarwal, Kosh, Marı́a Buti, Florian van Bömmel, et al.. (2024). JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. Journal of Hepatology. 81(3). 404–414. 22 indexed citations

Janssen, Harry L.A., Jinlin Hou, Tarik Asselah, et al.. (2023). Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut. 72(7). 1385–1398. 31 indexed citations

Lawitz, Eric, Fred Poordad, Julio Gutiérrez, et al.. (2020). Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study. Health Science Reports. 3(2). e145–e145. 5 indexed citations

Slaets, Leen, Filip De Ridder, Oliver Lenz, et al.. (2020). Systematic review with meta‐analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy. 2(3). 106–116. 3 indexed citations

Fontana, Robert J., Mark Avigan, Harry L.A. Janssen, et al.. (2019). Liver safety assessment in clinical trials of new agents for chronic hepatitis B. Journal of Viral Hepatitis. 27(2). 96–109. 11 indexed citations

Bourgeois, Stefan, Yves Horsmans, Frederik Nevens, et al.. (2017). Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. Antimicrobial Agents and Chemotherapy. 61(12). 6 indexed citations

Snoeys, Jan, Maria Beumont, Mario Monshouwer, & Sivi Ouwerkerk‐Mahadevan. (2016). Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics. 56(7). 781–792. 8 indexed citations

Meyer, Sandra De, Anne Ghys, Inge Dierynck, et al.. (2014). Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir. Virology Journal. 11(1). 93–93. 4 indexed citations

Scott, Jane, Kathleen Rosa, Min Fu, et al.. (2014). Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases. 14(1). 465–465. 16 indexed citations

10.

Sullivan, James C., Sandra De Meyer, Doug J. Bartels, et al.. (2013). Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. Clinical Infectious Diseases. 57(2). 221–229. 114 indexed citations

11.

Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2012). Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure. Journal of Hepatology. 58(3). 488–494. 10 indexed citations

12.

Meyer, Sandra De, Inge Dierynck, Anne Ghys, et al.. (2012). Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial. Hepatology. 56(6). 2106–2115. 35 indexed citations

13.

Zeuzem, Stefan, Pietro Andreoné, Stanislas Pol, et al.. (2011). 5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN. Journal of Hepatology. 54. S3–S3. 23 indexed citations

14.

Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). 6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION. Journal of Hepatology. 54. S3–S4. 21 indexed citations

15.

Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results: Abstract OP03 Table 1. Gut. 60(Suppl 2). A50.3–A51. 5 indexed citations

16.

Lenz, Oliver, Bart Fevery, Leen Vijgen, et al.. (2011). TMC435 IN COMBINATION WITH PEGINTERFERON ALPHA-2A/RIBAVIRIN IN TREATMENT-NAiVE PATIENTS INFECTED WITH HCV GENOTYPE 1: VIROLOGY ANALYSIS OF THE PILLAR STUDY. Hepatology. 54. 8 indexed citations

17.

Meyer, Sandra De, et al.. (2010). 251 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF GENOTYPE 2/3 HCV VARIANTS IN PATIENTS TREATED WITH TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN STUDY C209. Journal of Hepatology. 52. S106–S106. 1 indexed citations

18.

Marcellin, Patrick, Xavier Forns, Tobias Goeser, et al.. (2010). Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C. Gastroenterology. 140(2). 459–468.e1. 114 indexed citations

19.

Beumont, Maria & Mindy G. Schuster. (1999). Is an observation period necessary after intravenous antibiotics are changed to oral administration?. The American Journal of Medicine. 106(1). 114–116. 12 indexed citations

20.

Beumont, Maria, et al.. (1995). Veillonella Myositis in an Immunocompromised Patient. Clinical Infectious Diseases. 21(3). 678–679. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact